Otsuka Holdings (4578) FY2026 Q2 Earnings Report

Quick View

Executive Summary

Cumulative results for 2026 fiscal year Q2 reflected increases in both revenue and profit, with improvements in both the operating margin and net profit margin being the key highlights. Revenue was ¥1 trillion 3,323.9B (+12.8% YoY), Operating Income was ¥2,785.4B (+15.0%), and Net Income attributable to owners of the parent was ¥2,156.1B (+24.3%). Expansion in the Pharmaceuticals segment drove revenue growth, and revenue growth translated into profit growth while maintaining a gross margin of 72.5%, resulting in higher revenue and profit.

Factors Affecting Performance

【Revenue】Revenue was ¥1 trillion 3,323.9B, up +12.8% YoY. By segment, the core Pharmaceuticals segment led overall performance with revenue of ¥9,516.1B (71.4% of total, +14.1% YoY), followed by Nutraceuticals at ¥3,001.3B (+8.7%), Other Businesses at ¥632.1B (+14.7%), and Consumer Products at ¥174.4B (+10.1%). All segments achieved revenue growth.

【Profit and Loss】Operating Income was ¥2,785.4B (+15.0%), and the operating margin improved to 20.9% from 20.5% in the same period of the previous year. The Pharmaceuticals segment’s 26.3% profit margin lifted overall results, while Pharmaceuticals (+16.3%) and Other Businesses (+23.0%) recorded profit growth exceeding revenue growth. Profit Before Tax was ¥2,854.2B (+26.1%), exceeding the growth rate of Operating Income, aided by financial income of ¥116.3B exceeding financial expenses of ¥47.6B. Net Income reached ¥2,156.1B (+24.3%), resulting in higher revenue and profit.

Segment Analysis

The Pharmaceuticals segment is the core business, with revenue of ¥9,516.1B (71.4% of total, +14.1% YoY), Operating Income of ¥2,504.1B (+16.3%), and a profit margin of 26.3%. Nutraceuticals generated revenue of ¥3,001.3B (+8.7%), while profit was ¥368.5B (+0.5%), remaining nearly flat, and the profit margin stood at only 12.3%, indicating the impact of higher costs and expenses. Other Businesses recorded revenue of ¥632.1B (+14.7%) and profit of ¥61.6B (+23.0%), representing increases in both revenue and profit, although the profit margin was low at 9.8%. Consumer Products generated revenue of ¥174.4B (+10.1%) and profit of ¥138.1B (+7.4%), with an exceptionally high profit margin of 79.2%, although the segment remains small in scale. Overall, the scale and profitability of Pharmaceuticals constitute the center of the Company’s performance.

Key Financial Indicators

【Profitability】The operating margin was 20.9%, improving from 20.5% in the same period of the previous year, while the net profit margin increased to 16.2% from 14.7%. The gross margin remained almost flat at 72.5%, and the R&D expense ratio declined to 12.9% from 13.8% in the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥2,171.1B, or 1.01 times Net Income of ¥2,156.1B, indicating good cash conversion of earnings.【Investment Efficiency】Annualized ROE was 13.2%, primarily supported by the high net profit margin, with limited reliance on financial leverage.【Financial Soundness】The Equity Ratio remained high at 73.7% (equivalent to 73.7% in the previous year), while bonds and borrowings were small relative to total assets, indicating a stable financial foundation.

Cash Flow Analysis

Operating Cash Flow was ¥2,171.1B, nearly flat at +2.1% YoY, although an increase in inventories of ¥349.2B was a source of cash outflow, and income taxes paid of ¥483.7B also weighed on OCF. Investing Cash Flow was an outflow of ¥1,730.1B, primarily reflecting the acquisition of intangible assets of ¥1,292.7B. Including capital expenditures of ¥449.4B, Free Cash Flow amounted to only ¥441.0B. Financing Cash Flow was an outflow of ¥1,143.2B, mainly comprising dividend payments of ¥388.5B and share repurchases of ¥299.3B. As a result, the combined amount of dividends and share repurchases, ¥687.8B, exceeded Free Cash Flow of ¥441.0B, meaning that total shareholder returns during the period were also supported by the existing funding base, including cash and cash equivalents of ¥4,695.5B.

Earnings Quality

Operating Cash Flow was 1.01 times Net Income, and the divergence between accounting profit and cash flow was limited, indicating generally good earnings quality. The difference between Profit Before Tax of ¥2,854.2B and Operating Income of ¥2,785.4B was primarily attributable to net financial income, with financial income of ¥116.3B exceeding financial expenses of ¥47.6B, and equity-method income of ¥202.1B. These represent recurring components of the earnings structure rather than temporary factors related to the core business. Meanwhile, inventories increased by +¥395.9B YoY, indicating deterioration in working capital that reduced OCF. No temporary factors corresponding to extraordinary gains or losses were explicitly disclosed in the available data, and profit growth was supported by improved Operating Income and the stable accumulation of financial and equity-method income.

Earnings Forecasts and Guidance

The full-year forecast calls for Revenue of ¥2 trillion 7,250B, Operating Income of ¥4,690B (-2.2% YoY), and Net Income of ¥3,600B (-2.2%). As of the current quarter, revisions have been made to the earnings and dividend forecasts. The Q2 cumulative progress rates were 48.9% for Revenue, 59.4% for Operating Income, and 60.7% for Net Income, with progress on the profit lines exceeding the standard 50% level. The full-year plan itself assumes a decline in profit YoY, and is characterized by its assumption of lower profit margins or higher expenses toward the second half.

Shareholder Returns

The Q2 dividend was ¥100 per share, resulting in dividend payments of ¥388.5B. The Payout Ratio based solely on dividends relative to Net Income of ¥2,156.1B was approximately 18.0%. Including share repurchases of ¥299.3B, total shareholder returns amounted to ¥687.8B, resulting in a Total Return Ratio relative to Net Income of approximately 31.9%. The full-year dividend forecast is ¥200 per share, increased from the previous year’s dividend of ¥70. Dividend payments of ¥388.5B can be covered by Free Cash Flow of ¥441.0B; however, total shareholder returns including share repurchases exceeded Free Cash Flow, meaning the sustainability of returns will depend on investment intensity and working capital trends.

Risk Factors

1. Increase in inventory levels: Inventories amounted to ¥4,139.1B, an increase of +¥395.9B YoY, reducing Operating Cash Flow by ¥349.2B. Consistency with the demand outlook and the status of inventory accumulation will require monitoring.

2. Decline in the R&D expense ratio: R&D expenses were ¥1,721.7B, or 12.9% of Revenue, down from 13.8% in the same period of the previous year. While the slower growth in R&D expenses relative to revenue growth contributed to short-term margin improvement, its impact on medium- to long-term pipeline creation capacity requires monitoring.

3. Scale of goodwill and intangible assets: The Company held goodwill of ¥5,262.9B and intangible fixed assets of ¥6,910.5B, and acquired ¥1,292.7B of intangible fixed assets during the period. Because IFRS does not require goodwill to be amortized on a straight-line basis, future impairment test results could affect profit.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Because disclosed median data are unavailable, it is not possible to determine whether the Company’s operating margin and net profit margin are superior or inferior to the industry; however, both indicate a high level of profitability.

Growth and Capital Efficiency

Similarly, relative comparison is limited because median data were not provided, but revenue growth of 12.8% is considered to indicate a certain level of growth within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings

1. The operating margin of 20.9% and net profit margin of 16.2% both improved from the same period of the previous year, confirming a structure in which operating leverage from revenue growth and improved net financial income supported profit growth.

2. The increase in inventories weighed on Operating Cash Flow, and inventory trends will be a key factor influencing future cash flow performance.

3. While the full-year plan assumes a 2.2% decline in profit YoY, the profit progress rate as of Q2 was high at over 60%; therefore, changes in the expense structure and profit margins in the second half will be key factors determining full-year results.

Theoretical Share Price (Reference Value)

Sensitivity: ¥6,574–¥6,968 at ±1% for the cost of equity, and ¥6,752–¥6,789 at ±0.1 for ω.

Notes:

• Because the progress of Net Income against the full-year forecast (61%) exceeds the standard level (50%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts. In businesses with strong seasonality, the adjustment may be excessive).
• Net assets as of the quarter-end are used (there is a time lag relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---